LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
Data presented at AAIC 2026 show Eisai and Biogen's LEQEMBI subcutaneous autoinjector is bioequivalent to the IV formulation, with an exposure ratio of 104%. The 500 mg weekly subcutaneous dose demonstrated comparable efficacy and safety to the 10 mg/kg every two weeks IV regimen, including consistent amyloid clearance and a low 1.4% incidence of anti-drug antibodies.
Key figures
- Drug Name
- LEQEMBI (lecanemab)
- Ada incidence
- 1.4%
- Exposure ratio
- 104%
- Confidence interval
- 99.1%–109%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.